From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Precision Diagnostics.
Now with FDA clearance, this is our core technology platform, incorporating diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy. It's the first modular software-based system for clinical diagnostics.
The FDA-cleared AXINON® LDL-p Test System, is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.
Currently, Numares is the only company in the US selling an FDA-cleared NMR test.
A second Numares assay, the AXINON® GFR(NMR) kidney function assay, is available as a CE-labled in vitro diagnostic product in the EU and as a research-use-only product in the US.
The AXINON® HCC(NMR), a liver assessment and cancer early detection test, is in development.
Cardiology
AXINON® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.
AXINON® lipoFIT®: For cardiovascular risk assessment.
Available as a CE-labled in vitro diagnostic product in the EU and as a research-use-only product in the US.
Nephrology
AXINON® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.
Available as a CE-labled in vitro diagnostic product in the EU and as a research-use-only product in the US.
Hepatology
AXINON® HCC(NMR): Liver risk assessment and cancer early detection test.
In development.
